Abstract | PURPOSE: PATIENTS AND METHODS: Eleven patients with mild but symptomatic Paget's disease and one patient with very severe disease were treated with AHPrBP administered as a single intravenous infusion of 60 mg over 24 hours. Follow-up with clinical and biochemical evaluations was performed over six months for all patients, and over one year for seven patients. RESULTS: Clinical improvement and normalization of biochemical parameters were observed in all patients except one with extremely severe disease. On average, plasma alkaline phosphatase activity fell progressively and significantly from 256 +/- 29 U/liter (mean +/- SEM) to 97 +/- 6 U/liter after six months, and to 102 +/- 11 U/liter after one year (normal: less than 120 U/liter). Urinary excretion of hydroxyproline decreased within seven days to normal (from 4.3 +/- 0.5 mumol/liter of glomerular filtrate [lGF] to 1.7 +/- 0.2 mumol/lGF; normal: 2.2 mumol/lGF). Thereafter, it remained within the normal range until one year (1.8 +/- 0.2 mumol/lGF after six months and 1.9 +/- 0.3 mumol/lGF after one year). Side effects were negligible. Two patients noted only a transient increase in body temperature. When bone scintigraphy was repeated after six months, it revealed a marked decrease of the activity of the disease. CONCLUSION: Due to the important and sustained inhibition of bone resorption induced by AHPrBP, a single infusion of 60 mg of the bisphosphonate leads to a rapid decline in activity and a long-standing remission of moderate Paget's disease, without significant side effects.
|
Authors | D Thiébaud, P Jaeger, C Gobelet, A F Jacquet, P Burckhardt |
Journal | The American journal of medicine
(Am J Med)
Vol. 85
Issue 2
Pg. 207-12
(Aug 1988)
ISSN: 0002-9343 [Print] United States |
PMID | 3261129
(Publication Type: Journal Article)
|
Chemical References |
- Calcium-Binding Proteins
- Diphosphonates
- Osteocalcin
- Alkaline Phosphatase
- Pamidronate
- Hydroxyproline
|
Topics |
- Aged
- Aged, 80 and over
- Alkaline Phosphatase
(blood)
- Calcium-Binding Proteins
(blood)
- Diphosphonates
(administration & dosage, therapeutic use)
- Drug Administration Schedule
- Female
- Humans
- Hydroxyproline
(urine)
- Infusions, Intravenous
- Male
- Middle Aged
- Osteitis Deformans
(blood, drug therapy, urine)
- Osteocalcin
- Pamidronate
|